Medication management of chronic heart failure in older adults (Q38126374)

29 August 2017

Medication management of chronic heart failure in older adults (English)

1 reference

29 August 2017

0 references

chronic heart failure

1 reference

2

Maciej Banach

1 reference

29 August 2017

Ali Ahmed

4

0 references

Wilbert S Aronow

series ordinal

5

object named as

Wilbert S Aronow

1 reference

29 August 2017

Kannayiram Alagiakrishnan

series ordinal

1

1 reference

PubMed ID

23912673

29 August 2017

Linda G Jones

series ordinal

3

1 reference

29 August 2017

1 October 2013

1 reference

29 August 2017

1 reference

29 August 2017

30

1 reference

29 August 2017

10

1 reference

29 August 2017

765-782

1 reference

https://scigraph.springernature.com/pub.10.1007/s40266-013-0105-9

29 August 2017

0 references

cites work

Heart Disease and Stroke Statistics--2010 Update: A Report From the American Heart Association

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0105-9

Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0105-9

Long-term survival in patients older than 80 years hospitalised for heart failure. A 5-year prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0105-9

Management of octogenarians hospitalized for heart failure in Euro Heart Failure Survey I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0105-9

Heart failure in frail elderly patients: diagnostic difficulties, co-morbidities, polypharmacy and treatment dilemmas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0105-9

The pathophysiology of heart failure with preserved ejection fraction: from molecular mechanisms to exercise haemodynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0105-9

A propensity-matched study of the effects of chronic diuretic therapy on mortality and hospitalization in older adults with heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0105-9

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0105-9

Diuretic use, progressive heart failure, and death in patients in the DIG study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0105-9

Combination of loop diuretics with thiazide-type diuretics in heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0105-9

Metolazone and its role in edema management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0105-9

Combination therapy with metolazone and loop diuretics in outpatients with refractory heart failure: an observational study and review of the literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0105-9

Eplerenone in patients with systolic heart failure and mild symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0105-9

Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0105-9

Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0105-9

Effect of eplerenone versus spironolactone on cortisol and hemoglobin A₁(c) levels in patients with chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0105-9

Spironolactone improves diastolic function in the elderly.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0105-9

Update on diastolic heart failure or heart failure with preserved ejection fraction in the older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0105-9

Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0105-9

The meaning of hypokalemia in heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0105-9

What is the risk of hyperkalaemia in heart failure?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0105-9

Hypokalemia and outcomes in patients with chronic heart failure and chronic kidney disease: findings from propensity-matched studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0105-9

Hyperkalaemia in congestive heart failure patients using ACE inhibitors and spironolactone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0105-9

Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0105-9

Frequency and predictors of hyperkalemia in patients ≥60 years of age with heart failure undergoing intense medical therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0105-9

Use of diuretics in the treatment of heart failure in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0105-9

Treatment of systolic and diastolic heart failure in the elderly

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0105-9

Tolerability of spironolactone as adjunctive treatment for heart failure in patients over 75 years of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0105-9

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0105-9

A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0105-9

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0105-9

Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0105-9

Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0105-9

Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0105-9

Perindopril improves six minute walking distance in older patients with left ventricular systolic dysfunction: a randomised double blind placebo controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0105-9

Survival benefits of angiotensin-converting enzyme inhibitors in older heart failure patients with perceived contraindications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0105-9

Angiotensin II receptor blockers in patients with ACE inhibitor-induced angioedema

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0105-9

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0105-9

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0105-9

Additive effects of spironolactone and candesartan on cardiac sympathetic nerve activity and left ventricular remodeling in patients with congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0105-9

A randomized double-blind trial of enalapril in older patients with heart failure and preserved ejection fraction: effects on exercise tolerance and arterial distensibility.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0105-9

Irbesartan in patients with heart failure and preserved ejection fraction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0105-9

Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0105-9

The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0105-9

Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0105-9

Pharmacotherapy for heart failure in patients with renal insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0105-9

Management of heart failure in primary care (the IMPROVEMENT of Heart Failure Programme): an international survey.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0105-9

Practical recommendations for the use of ACE inhibitors, beta-blockers and spironolactone in heart failure: putting guidelines into practice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0105-9

Relation of baseline systolic blood pressure and long-term outcomes in ambulatory patients with chronic mild to moderate heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0105-9

Results from post-hoc analyses of the CIBIS II trial: effect of bisoprolol in high-risk patient groups with chronic heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0105-9

Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0105-9

Effect of carvedilol on survival in severe chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0105-9

Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0105-9

Effects of nebivolol in elderly heart failure patients with or without systolic left ventricular dysfunction: results of the SENIORS echocardiographic substudy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0105-9

A comparative analysis of the results from 4 trials of beta-blocker therapy for heart failure: BEST, CIBIS-II, MERIT-HF, and COPERNICUS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0105-9

Bucindolol, systolic blood pressure, and outcomes in systolic heart failure: a prespecified post hoc analysis of BEST

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0105-9

Differential impact of heart rate and blood pressure on outcome in patients with heart failure with reduced versus preserved left ventricular ejection fraction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0105-9

Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0105-9

Dose of metoprolol CR/XL and clinical outcomes in patients with heart failure: analysis of the experience in metoprolol CR/XL randomized intervention trial in chronic heart failure (MERIT-HF).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0105-9

Association between resting heart rate, chronotropic index, and long-term outcomes in patients with heart failure receiving β-blocker therapy: data from the HF-ACTION trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0105-9

B-CONVINCED: Beta-blocker CONtinuation Vs. INterruption in patients with Congestive heart failure hospitalizED for a decompensation episode.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0105-9

Long-term prognostic importance of resting heart rate in patients with left ventricular dysfunction in connection with either heart failure or myocardial infarction: the DIAMOND study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0105-9

Carvedilol in elderly patients with chronic heart failure, a 12 weeks randomized, placebo controlled open trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0105-9

Effect on survival and hospitalization of initiating treatment for chronic heart failure with bisoprolol followed by enalapril, as compared with the opposite sequence: results of the randomized Cardiac Insufficiency Bisoprolol Study (CIBIS) III.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0105-9

Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0105-9

A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0105-9

Combination of isosorbide dinitrate and hydralazine in blacks with heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0105-9

Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0105-9

Effects of combined administration of low dose atorvastatin and vitamin E on inflammatory markers and endothelial function in patients with heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0105-9

Atorvastatin therapy increases heart rate variability, decreases QT variability, and shortens QTc interval duration in patients with advanced chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0105-9

Heart failure management using implantable devices for ventricular resynchronization: Comparison of Medical Therapy, Pacing, and Defibrillation in Chronic Heart Failure (COMPANION) trial. COMPANION Steering Committee and COMPANION Clinical Investiga

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0105-9

Rosuvastatin in older patients with systolic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0105-9

Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0105-9

Effect of atorvastatin in patients with chronic heart failure - insights from randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0105-9

Statins in heart failure: the paradox between large randomized clinical trials and real life.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0105-9

Statin therapy may be associated with lower mortality in patients with diastolic heart failure: a preliminary report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0105-9

Does aspirin attenuate the beneficial effects of angiotensin-converting enzyme inhibition in heart failure?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0105-9

Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0105-9

Warfarin and aspirin in patients with heart failure and sinus rhythm

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0105-9

Genetic tailoring of pharmacotherapy in heart failure: optimize the old, while we wait for something new.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0105-9

Noncardiac comorbidity increases preventable hospitalizations and mortality among medicare beneficiaries with chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0105-9

Frequent non-cardiac comorbidities in patients with chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0105-9

Clinical characteristics and major comorbidities in heart failure patients more than 85 years of age compared with younger age groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0105-9

The diversity of heart failure in a hospitalized population: the role of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0105-9

Co-morbidity and potential treatment conflicts in elderly heart failure patients: a retrospective, cross-sectional study of administrative claims data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0105-9

Chronic obstructive pulmonary disease in heart failure. Prevalence, therapeutic and prognostic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0105-9

Consumption of NSAIDs and the development of congestive heart failure in elderly patients: an underrecognized public health problem.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0105-9

Beta-blockers and inspiratory pulmonary function in chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0105-9

ACE inhibitor-induced bronchial reactivity in patients with respiratory dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0105-9

Ferric carboxymaltose in patients with heart failure and iron deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0105-9

Precipitating factors for delirium in hospitalized elderly persons. Predictive model and interrelationship with baseline vulnerability.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0105-9

Beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0105-9

The clinical implications of cognitive impairment in elderly patients with chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0105-9

Cognitive impairment in heart failure: a systematic review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0105-9

Heart failure comorbidities at the end of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0105-9

End-of-life preferences of elderly patients with chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0105-9

Beta-blockers and angiotensin-converting enzyme inhibitors/receptor blockers prescriptions after hospital discharge for heart failure are associated with decreased mortality in Alberta, Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0105-9

The effects of beta-blockers on morbidity and mortality in a population-based cohort of 11,942 elderly patients with heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0105-9

The EuroHeart Failure Survey programme--a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0105-9

American College of Cardiology/American Heart Association Chronic Heart Failure Evaluation and Management guidelines: relevance to the geriatric practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0105-9

Patterns of pharmacologic treatment of congestive heart failure in elderly nursing home residents and related issues: a review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0105-9

Contemporary management of octogenarians hospitalized for heart failure in Europe: Euro Heart Failure Survey II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0105-9

Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0105-9

The effect of KW-3902, an adenosine A1 receptor antagonist, on renal function and renal plasma flow in ambulatory patients with heart failure and renal impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0105-9

Sildenafil stops progressive chamber, cellular, and molecular remodeling and improves calcium handling and function in hearts with pre-existing advanced hypertrophy caused by pressure overload

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0105-9

Sildenafil and diastolic dysfunction after acute myocardial infarction in patients with preserved ejection fraction: the Sildenafil and Diastolic Dysfunction After Acute Myocardial Infarction (SIDAMI) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0105-9

PhosphdiesteRasE-5 Inhibition to Improve CLinical Status and EXercise Capacity in Diastolic Heart Failure (RELAX) trial: rationale and design

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0105-9

Novel therapies in acute and chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40266-013-0105-9

Usefulness of verapamil for congestive heart failure associated with abnormal left ventricular diastolic filling and normal left ventricular systolic performance

21 January 2018

1 reference

12 December 2020

A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure

1 reference

12 December 2020

Do elderly systolic heart failure patients benefit from beta blockers to the same extent as the non-elderly? Meta-analysis of >12,000 patients in large-scale clinical trials

1 reference

12 December 2020

Diuretics for heart failure

1 reference

12 December 2020

Optimizing Pharmacotherapy in Older Patients

1 reference

12 December 2020

Appropriate use of digoxin in treating older nursing home patients with heart failure

1 reference

12 December 2020

Heart failure update: treatment of heart failure with a normal left ventricular ejection fraction in the elderly

1 reference

12 December 2020

Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors

1 reference

12 December 2020

Depressive symptoms and risk of functional decline and death in patients with heart failure

1 reference

12 December 2020

Plasma adenosine levels increase in patients with chronic heart failure

1 reference

12 December 2020

Time for new indications for statins?

1 reference

12 December 2020

2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults

1 reference

12 December 2020

Efficacy and safety of tolvaptan in heart failure patients with volume overload despite the standard treatment with conventional diuretics: a phase III, randomized, double-blind, placebo-controlled study (QUEST study)

1 reference

12 December 2020

Management of heart failure among very old persons living in long-term care: has the voice of trials spread? The SAGE Study Group

1 reference

12 December 2020

The perindopril in elderly people with chronic heart failure (PEP-CHF) study

1 reference

12 December 2020

Effect of enalapril on congestive heart failure treated with diuretics in elderly patients with prior myocardial infarction and normal left ventricular ejection fraction

1 reference

12 December 2020

Incidence, clinical predictors, and prognostic impact of worsening renal function in elderly patients with chronic heart failure on intensive medical therapy

1 reference

12 December 2020

Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction

1 reference

12 December 2020

The Persistent Exclusion of Older Patients From Ongoing Clinical Trials Regarding Heart Failure

1 reference

12 December 2020

Sex-based differences in the effect of digoxin for the treatment of heart failure

1 reference

12 December 2020

Effect of age on mortality, hospitalizations and response to digoxin in patients with heart failure: the DIG study

1 reference

12 December 2020

Effects of angiotensin-converting enzyme inhibitors and digoxin on health outcomes of very old patients with heart failure. SAGE Study Group. Systematic Assessment of Geriatric drug use via Epidemiology

1 reference

12 December 2020

1 reference

12 December 2020

The prognostic importance of anemia in patients with heart failure

1 reference

12 December 2020

Association of serum digoxin concentration and outcomes in patients with heart failure

1 reference

12 December 2020

Comparison of neurohumoral effects of short-acting and long-acting loop diuretics in patients with chronic congestive heart failure

1 reference

12 December 2020

Long-term use of sildenafil in the therapeutic management of heart failure

1 reference

12 December 2020

Effects of the 1994 Canadian Cardiovascular Society clinical practice guidelines for congestive heart failure.

1 reference

12 December 2020

Effect of propranolol versus no propranolol on total mortality plus nonfatal myocardial infarction in older patients with prior myocardial infarction, congestive heart failure, and left ventricular ejection fraction > or = 40% treated with diuretics

1 reference

12 December 2020

Superiority of long-acting to short-acting loop diuretics in the treatment of congestive heart failure

1 reference

12 December 2020

Comparative analysis of the therapeutic effects of long-acting and short-acting loop diuretics in the treatment of chronic heart failure using (123)I-metaiodobenzylguanidine scintigraphy

1 reference

12 December 2020

The effect of digoxin on mortality and morbidity in patients with heart failure

1 reference

12 December 2020

Warfarin anticoagulation and survival: a cohort analysis from the Studies of Left Ventricular Dysfunction

1 reference

12 December 2020

Failure of benefit and early hazard of bucindolol for Class IV heart failure

1 reference

12 December 2020

10.1007/S40266-013-0105-9

Identifiers

DOI

1 reference

29 August 2017

1 reference

PubMed ID

23912673